NCI-MATCH / EAY131 Findings and Publications

Treatment arm findings and publications on special topics about the NCI-MATCH precision medicine trial appear on a rolling basis. This section of the website contains a comprehensive list of all publications associated with the trial. See the table below. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.

We update this table on an ongoing basis as new publications appear.

TopicTitle and Citation
Arm E Final Results

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

Chen MF. JCO Precis Oncol. February 2024

ImplementationThe NCI-MATCH trial: lessons for precision oncology
O'Dwyer PJ. Nature Medicine. June 2023
Arm Z1B Final ResultsPhase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Clark AS. Clin Cancer Res. April 2023
Arms S1 & S2 Final ResultsTrametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Wisinski KB. JCO Precis Oncol. April 2023
Arm B Final Results

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Bedard PL. JCO Precis Oncol. August 2022

Arms F & G Final Results

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Mansfield AS, NPJ Precis Oncol. March 2022

Arm I Final Results

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Krop IE. JCO Precis Oncol. February 2022

Arm Z1F Final Results

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Damodaran S, J Clin Oncol. February 2022

Arm Z1A Final ResultsDifferential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
Cleary JM. Clin Cancer Res. June 2021
Arm Y Final ResultsEffect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kalinsky KM. JAMA Oncol. December 2020
Central Screening CohortMolecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Flaherty KT, J Clin Oncol. October 2020
Physician SurveyTumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial
Chen AP, JCO Precis Oncol. October 2020
Arm H Final ResultsDabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Salama AKS. J Clin Oncol. August 2020
Arm W Final ResultsPhase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Chae YK. J Clin Oncol. May 2020
Arm R Final ResultsTrametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)
Johnson DB. Clin Cancer Res. April 2020
ImplementationThe Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty KT. J Natl Cancer Inst. January 2020
Arm Z1D Final ResultsNivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Azad NS. J Clin Oncol. January 2020
Arm Q Final ResultsAdo-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q
Jhaveri KL. Ann Oncol. November 2019
Immunohistochemical AssaysValidation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Koury JD. Clin Cancer Res. January 2018
Next-Gen Sequencing AssayConsiderations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience
Lih CJ. Curr Probl Cancer. May-June 2017
Defining PrecisionDefining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
O'Sullivan Coyne G. Curr Probl Cancer. May-June 2017
Next-Gen Sequencing AssayAnalytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
Molecular Analysis for Therapy Choice Clinical Trial
Lih CJ. J Mol Diagn. March 2017
OverviewAn overview of the NCI Precision Medicine trials-NCI MATCH and MPACT
Do K. Chin Clin Oncol. September 2015
OverviewMolecular Analysis for Therapy Choice: NCI MATCH
Conley BA. Semin Oncol. June 2014
ECOG-ACRIN Cancer Research Group